Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Rating)’s share price rose 1.4% on Monday . The stock traded as high as $1.40 and last traded at $1.40. Approximately 1,936,226 shares were traded during trading, an increase of 48% from the average daily volume of 1,306,067 shares. The stock had previously closed at $1.38.
Citius Pharmaceuticals Trading Down 0.8 %
The company’s 50 day moving average price is $1.07 and its two-hundred day moving average price is $1.10. The firm has a market cap of $172.53 million, a PE ratio of -5.41 and a beta of 1.21.
Citius Pharmaceuticals (NASDAQ:CTXR – Get Rating) last issued its quarterly earnings results on Thursday, December 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Equities research analysts expect that Citius Pharmaceuticals, Inc. will post 0.43 earnings per share for the current fiscal year.
Institutional Trading of Citius Pharmaceuticals
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite.
- Get a free copy of the StockNews.com research report on Citius Pharmaceuticals (CTXR)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.